Navigation Links
Spectral appoints Anthony Bihl to Board of Directors
Date:3/6/2008

TORONTO, March 6 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc. (TSX:SDI) today announced that Mr. Anthony Bihl has been appointed to the Company's Board of Directors.

"As the former CEO of Siemens Medical Solutions Diagnostics, a combination of the former Bayer Diagnostics and Diagnostic Products Corporation, Mr. Bihl will be a valuable addition to our Board," said Dr. Paul Walker, President and CEO of Spectral Diagnostics. "Mr. Bihl is a 25 year veteran in the field of diagnostics and is well-suited to advise Spectral on our global commercialization strategy of the EAA(TM) Endotoxin Activity Assay, the only FDA cleared diagnostic for the measurement of endotoxin."

Mr. Bihl has more than 25 years of experience with diagnostic products, having held leadership roles in global healthcare businesses, including a broad base of operational and executive positions in large and medium multinational healthcare firms. Before his role as CEO of Siemens Medical Solutions Diagnostics, Mr. Bihl served in senior leadership roles at Bayer Healthcare Diagnostics, having held the roles of Senior VP of Finance and Administration and President, responsible for all aspects of this worldwide business Division. Prior to his tenure at Bayer, Mr. Bihl gained extensive operational experience through more than 20 years at E.I. DuPont Inc. His final role at DuPont was as Plant Manager for medical instrument manufacturing.

Mr. Bihl received a Bachelor's Degree in Business Administration from Pennsylvania State University, and is a member of the Board of Directors for Adnavance Technologies Inc.

About Spectral Diagnostics

Spectral is a developer of innovative technologies for comprehensive disease management. Spectral's lead product is its EAA(TM) Endotoxin Activity Assay, the only FDA approved diagnostic for the measurement of endotoxin. Spectral technologies provide accurate and timely information to clinicians enabling the early initiation of appropriate and targeted therapy. Spectral is listed on TSX under the symbol SDI.

Forward-looking statement

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.

The TSX has not reviewed and does not accept responsibility for the

adequacy or accuracy of this statement.


'/>"/>
SOURCE Spectral Diagnostics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Spectral announces data on the clinical utility of EAA(TM) to be presented at 12th Annual Critical Care for Endotoxemia Conference in Japan
2. CRi Announces Nuance 2, the Next-Generation Multispectral Imaging System for Brightfield and Fluorescent-Based Microscopy
3. US Patent and Trademark Office Allows CRis Patent Application for Spectral Imaging of Deep Tissue
4. Spectral partner launches EAA(TM) Rapid Sepsis Diagnostic in Germany
5. Tianyin Pharmaceutical Appoints Three New Independent Board Members
6. Hiemstra Appoints Robert C. Glines as Director of Business Development
7. Tengion Appoints Jeff Randall to Board of Directors
8. Ambrx Appoints Douglas Axelrod Senior Vice President for Clinical Research and Development
9. BioStorage Technologies Appoints Dr. Wolfgang Hoffer as Managing Director of European Operations
10. Stem Cell Company t2cure Appoints Dr Rueck Head of Clinical Operations
11. Human Genome Sciences Appoints Maxine Gowen, Ph.D., to Its Board Of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... 2017  UBM and the Massachusetts Medical Device ... partnership and the third annual Massachusetts Medtech Week. Massachusetts ... st Annual MassMEDIC Conference held in conjunction ... 2017. MassMEDIC will feature a ... and CEO, Scott Whitaker , at its ...
(Date:3/22/2017)... New York , March 22, 2017 ... is largely fragmented, states a research report by Transparency ... S.A., Pfizer Inc., Amgen Inc., and AbbVie Inc., accounted ... in 2015. The prominent players in this market are ... expand their product portfolio, which is likely to lead ...
(Date:3/22/2017)... 22, 2017   VWR (NASDAQ: ... product and service solutions to laboratory and ... acquired EPL Archives, Inc., an international biorepository ... entire regulated product research, development and commercialization ... and ancillary services. EPL Archives is widely ...
(Date:3/22/2017)... , ... March 21, 2017 , ... Benchworks ... Chief Executive Officer Forum on March 23-24 in San Diego. The event is ... and diagnostic industries. , Benchworks Vice President Christian Meyer will also participate in ...
Breaking Biology Technology:
(Date:3/2/2017)... 2, 2017 Summary This report ... Merck KGaA and its partnering interests and activities since ... Description The Partnering Deals and Alliance since 2010 ... of one of the world,s leading life sciences companies. ... purchase to ensure inclusion of the most up to ...
(Date:3/1/2017)... , March 1, 2017  Aware, Inc. (NASDAQ: ... announced that Richard P. Moberg has resigned, ... co-President and Chief Financial Officer and Treasurer of Aware ... to serve as a member of the Board of ... , Aware,s co-Chief Executive Officer and co-President, General Counsel ...
(Date:2/28/2017)...  EyeLock LLC, ein marktführendes Unternehmen im Bereich ... Lösung zur Iris-Erkennung auf der neuesten Mobilplattform ... dem Mobile World Congress 2017 (27. Februar ... 3, Stand 3E10, vorstellen. Der ... – eine Kombination aus Hardware, Software und ...
Breaking Biology News(10 mins):